Nanox.AI Advances Commercial Collaboration with Dosy Health to Bring AI Cardiac Solution to Thailand

November 10, 2026

Collaboration builds on Dosy Health's established relationships with Mahidol University, Thammasat University and hospitals within the BDMS network, supporting planned distribution and commercialization in Thailand

PETACH TIKVA, Israel, [DATE] (GLOBE NEWSWIRE) -- Nano-X Imaging Ltd. (NASDAQ: NNOX) ("Nanox" or the "Company"), a leader in innovative medical imaging technology, today announced that its subsidiary, Nanox AI Ltd. ("Nanox.AI"), is advancing a commercial collaboration with Dosy Health ("Dosy"), a Thailand-based healthcare technology company, to support the planned introduction and commercialization of Nanox.AI's CT-based cardiac solution in Thailand.

The parties have signed a distribution agreement for Nanox.AI's cardiac solution, HealthCCSng. The proposed collaboration represents a step in Nanox.AI's strategy to expand its international commercial footprint and bring CT-based imaging analytics to additional healthcare markets.

Dosy Health maintains existing business relationships with Mahidol University and Thammasat University, alongside healthcare software activities with hospitals within the Bangkok Dusit Medical Services (BDMS) network. Its local healthcare relationships and software-integration capabilities could support engagement with healthcare stakeholders, evaluation of integration requirements and future market development.

Following participation by Dosy Health's CEO, Sahatus Asawadilockchai, in the Global Medical AI Summit in Thailand, several hospitals expressed interest in the proposed solutions, according to Dosy Health. These discussions remain preliminary and do not constitute purchase commitments.

Nanox.AI develops imaging analytics designed to extract additional clinical insights from existing CT scans. HealthCCSng analyzes routine non-contrast, non-gated CT scans that include the entire heart to provide coronary artery calcium measurements and categorization for clinician review.

Product availability and permitted uses vary by market and remain subject to applicable regulatory requirements.

"Every routine CT scan can hold insights that may otherwise go unnoticed, and expanding our international presence is a key part of Nanox.AI's commercialization strategy," said Erez Meltzer, Chief Executive Officer and Acting Chairman of Nanox. "Our developing collaboration with Dosy Health offers an opportunity to introduce our Cardiac solution, to Thailand's healthcare market. By combining our imaging analytics with Dosy's local market knowledge and software-integration capabilities, we aim to help clinicians see what matters, and to build a foundation for future commercial opportunities."

"We're seeing growing momentum for medical imaging AI in Thailand. The country has a large CT scanner base, with more scanners per capita than several Southeast Asian peers. For us, that's a significant opportunity to unlock more clinical value from existing CT scans and better inform patient care. We are proud to collaborate with Nanox.AI, which brings deep expertise in medical imaging AI and has developed U.S. FDA-cleared software. At Dosy, we bring experience developing AI and integrating software for Thai hospitals, including those in one of the country's largest private hospital groups. We have strong relationships with major hospitals, medical schools and public-sector organizations in Thailand. Together, we'll start with cardiac imaging and focus on bringing AI findings into the systems Thai clinicians already use, with room to explore bone and liver imaging over time," said Sahatus Asawadilockchai, Chief Executive Officer of Dosy Health.

The companies expect to continue discussions regarding proposed commercial arrangements, product training and regulatory preparation. Future commercialization is subject to definitive agreements, applicable regulatory requirements and market-development progress.

About Nanox

Nanox (NASDAQ: NNOX) is focused on driving the world's transition to preventive health care by delivering an integrated, end-to-end medical imaging and healthcare services platform.

Nanox combines affordable imaging hardware, advanced AI-based solutions, cloud-based software, access to remote radiology, health IT solutions, and a marketplace to enable earlier detection, improved clinical efficiency, and broader access to care.

Nanox's vision is to expand the reach of medical imaging both within and beyond traditional hospital settings by providing a seamless solution from scan to interpretation and beyond. By leveraging proprietary digital X-ray technology, AI-driven analytics, and a clinically driven approach, Nanox aims to enhance the efficiency of routine imaging workflows, support early detection of disease, and improve patient outcomes.

The Nanox ecosystem includes Nanox.ARC X, a multi-source digital tomosynthesis system designed to make advanced 3D imaging accessible in more clinical settings; Nanox.AI, a suite of AI-based algorithms that augment the interpretation of routine CT imaging to identify early signs often associated with chronic disease; Nanox.CLOUD, a cloud-based platform for secure data management, storage, and advanced imaging analytics; Nanox.MARKETPLACE and USARAD Holdings, which provides access to remote radiology and cardiology experts and comprehensive teleradiology services; and Nanox Health IT combines deep healthcare IT expertise with leading technology partners to deliver RIS, PACS, AI, dictation, and secure infrastructure solutions that streamline workflows and support safer, more efficient care delivery.

The Nanox.ARC X was selected as one of TIME's Best Inventions of 2026.



By integrating imaging technology, AI, cloud infrastructure, clinical expertise, a marketplace, and health information technology, Nanox seeks to lower barriers to adoption, improve utilization, and advance preventive care worldwide. For more information, please visit https://www.nanox.vision.

About Nanox.AI

Nanox.AI is the deep-learning medical imaging analytics subsidiary of Nanox. Nanox.AI solutions are developed to target highly prevalent chronic and acute diseases affecting large populations around the world. Leveraging AI, Nanox.AI helps clinicians extract valuable and actionable clinical insights from medical imaging that otherwise may go unnoticed, potentially initiating further medical assessment to establish individual preventative care pathways for patients. For more information, please visit www.nanox.vision/ai.

Forward-Looking Statements

This press release may contain forward-looking statements that are subject to risks and uncertainties. All statements that are not historical facts contained in this press release are forward-looking statements. Such statements include, but are not limited to, any statements relating to the initiation, timing, progress and results of the Company's research and development, manufacturing, and commercialization activities with respect to its X-ray source technology and the Nanox.ARC, the ability to realize the expected benefits of its recent acquisitions and the projected business prospects of the Company and the acquired companies. In some cases, you can identify forward-looking statements by terminology such as "can," "might," "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "could," "expect," "predict," "potential," or the negative of these terms or other similar expressions. Forward-looking statements are based on information the Company has when those statements are made or management's good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to (i) Nanox's ability to complete development of the Nanox System; (ii) Nanox's ability to successfully demonstrate the feasibility of its technology for commercial applications; (iii) Nanox's history of recurring losses and negative cash flows from operating activities, significant future commitments and the uncertainty regarding the adequacy of Nanox's liquidity to pursue its complete business objectives, and substantial doubt regarding its ability to continue as a going concern; (iv) Nanox's expectations regarding the necessity of, timing of filing for, and receipt and maintenance of, regulatory clearances or approvals regarding its technology, the Nanox.ARC and Nanox.CLOUD from regulatory agencies worldwide and its ongoing compliance with applicable quality standards and regulatory requirements; (v) Nanox's ability to realize the anticipated benefits of the acquisitions, which may be affected by, among other things, competition, brand recognition, the ability of the acquired companies to grow and manage growth profitably and retain their key employees; (vi) Nanox's ability to enter into and maintain commercially reasonable arrangements with third-party manufacturers and suppliers to manufacture the Nanox.ARC; (vii) the market acceptance of the Nanox System and the proposed pay-per-scan business model; (viii) Nanox's expectations regarding collaborations with third-parties and their potential benefits; (ix) Nanox's ability to conduct business globally; (x) changes in global, political, economic, business, competitive, market and regulatory forces; (xi) risks related to the current war between Israel and Hamas and any worsening of the situation in Israel; (xii) risks related to business interruptions resulting from the COVID-19 pandemic or similar public health crises, among other things; and (xiii) potential litigation associated with our transactions.

For a discussion of other risks and uncertainties, and other important factors, any of which could cause Nanox's actual results to differ from those contained in the Forward-Looking Statements, see the section titled "Risk Factors" in Nanox's Annual Report on Form 20-F for the year ended December 31, 2025, and subsequent filings with the U.S. Securities and Exchange Commission. The reader should not place undue reliance on any forward-looking statements included in this press release. Except as required by law, Nanox undertakes no obligation to update publicly any forward-looking statements after the date of this press release to conform these statements to actual results or to changes in the Company's expectations.

Contacts

Media Contact:
Ben Shannon
ICR Healthcare
NanoxPR@icrinc.com

Investor Contact:
Mike Cavanaugh
ICR Healthcare
mike.cavanaugh@icrhealthcare.com

NANOX